Australia's Microba Life Sciences slumps on weak Q3 revenue

Microba Life Sciences

30/04/2025 03:54

** Shares of Microba Life Sciences MAP.AX fall 17.8% to A$0.185

** Stock set for its weakest session since October 23, 2023- if current trends hold

** Health sciences co posts a 15% decline in Q3 revenue compared to last year

** But, co sees FY25 revenue to be up 26%-34% from last year

** Co set for its strongest month since January

** About 559,491 shares change hands, 3.7x the 30-day average of 152,712 shares

** Stock down 5.1% YTD, including current session's moves

(Reporting by Manasi Dasa in Bengaluru)

((Manasi.DasaSundeep@thomsonreuters.com;))